In the 30 years since the rabbit antithymocyte globulin (rATG) Thymoglobulin® was first licensed, there have been profound advances in its use, including a widening of its role in optimizing immunosuppression for solid organ transplant recipients and in hematology indications.

rATG dosing has decreased over time, refining the risk:benefit ratio and reducing early safety concerns.

A growing understanding of the complex immunological properties has prompted new research into other therapeutic fields.